Covalon Responds to FDA's Request for Further Information

Covalon Technologies announced that it has responded to the FDA's request for further information regarding the company's 510(k) premarket notification for its ColActive wound dressing. ColActive is a novel, proprietary collagen wound dressing developed by Covalon which will be marketed by Hartmann-Conco through an exclusive distribution agreement for the U.S.

ArriveNet (http://press.arrivenet.com/hea/article.php/616158.html)